Skip to main content
Top
Published in: Cancer Causes & Control 7/2008

01-09-2008 | Original Paper

Correction for under-ascertainment in cancer cases in the very elderly (aged 75+): external reference method

Authors: Mahdi Fallah, Elham Kharazmi

Published in: Cancer Causes & Control | Issue 7/2008

Login to get access

Abstract

Objective

Any fall-off in the age-specific cancer incidence curve in oldest age groups may be suggestive of under-ascertainment. This article introduces a correction method for under-ascertainment of cancer cases in the very elderly (aged 75+).

Methods

Corrected age-specific rates for a certain cancer are calculated by summing the age-specific rates of that cancer for two lower age groups multiplied by a corresponding coefficient from an external reference cancer registry (sex-, site-, and age-specific coefficients from the Finnish Cancer Registry, a nation-wide population-based registry with high data validity). In order to examine this new method, Lithuanian Cancer Registry data for the period 1993–97 was chosen as an example.

Results

Age-specific incidence curves of cancers in both sexes and most of cancer sites in Lithuania demonstrated the presence of under-ascertainment in the oldest age groups (over 75). Comparison of the corrected incidence rates for 1995 with the original ones showed that without correction for under-ascertainment, crude rates (and consequently number of new cases) were underestimated by around 10%. Underestimation for the year 2050 in Lithuania was ∼20%. Depending on cancer site and sex, the percentage of underestimation varied substantially.

Conclusion

In many cancer registries, after correction for under-ascertainment in elderly age groups, the estimates of number of new cases and incidence rates increase. With respect to prepare future projections of incidence, when the effects of an aging population need to be taken into account, accurate age-specific rates in the upper age groups are important. Without correction, cancer occurrence measures may be substantially underestimated, which may lead to inadequate resource allocations for cancer control.
Literature
1.
go back to reference Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL (1998) Completeness. Comparability and quality control in cancer registration. IARC Press, Lyon, p. 38 Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL (1998) Completeness. Comparability and quality control in cancer registration. IARC Press, Lyon, p. 38
2.
go back to reference Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents. IARC Press, Lyon Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents. IARC Press, Lyon
3.
go back to reference Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 33(4):365–369PubMedCrossRef Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 33(4):365–369PubMedCrossRef
4.
go back to reference Jensen OM, Parkin DM, Maclennau R, Mair CS, Skeet RG (1991) Cancer registration principles and methods. IARC Press, Lyon Jensen OM, Parkin DM, Maclennau R, Mair CS, Skeet RG (1991) Cancer registration principles and methods. IARC Press, Lyon
Metadata
Title
Correction for under-ascertainment in cancer cases in the very elderly (aged 75+): external reference method
Authors
Mahdi Fallah
Elham Kharazmi
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 7/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9136-7

Other articles of this Issue 7/2008

Cancer Causes & Control 7/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine